<DOC>
	<DOCNO>NCT01563523</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe , Oceania North America . The aim trial evaluate efficacy activate recombinant human factor VII give conjunction standard therapy treatment massive bleeding subject severe blunt and/or penetrate trauma injury .</brief_summary>
	<brief_title>Efficacy Safety Activated Recombinant Human Factor VII Severely Injured Trauma Patients</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Informed consent obtain subject and/or his/her legally authorise representative ( LAR ) trialrelated activity Injury ( y ) due blunt penetrate trauma Receipt 6 unit PRBC within 4 hour period follow admittance trauma centre Receipt 8 unit PRBC upon administration trial drug Prehospital cardiac arrest Cardiac arrest ER OR Gunshot wound head Glasgow Coma Scale 8 Base deficit 15 mEq/l severe acidosis Transfusion 8 unit PRBC prior arrival trauma centre</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>